Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43
- PMID: 21603977
- DOI: 10.1007/s12031-011-9551-1
Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43
Abstract
Most cases of frontotemporal lobar degeneration (FTLD) are characterized by the abnormal accumulation of either the microtubule-associated protein tau or the transactive response DNA-binding protein with M(r) 43 kDa, TDP-43 (FTLD-tau and FTLD-TDP, respectively). However, there remain ∼10% of cases, composed of a heterogenous collection of uncommon disorders, for which the molecular basis remains uncertain. In this review, we describe the characteristic genetic, clinical, and pathological features of the major tau/TDP-negative FTLD subtypes, with focus on recent advances in our understanding of their molecular basis. This includes the discovery that the pathological changes in atypical FTLD with ubiquitinated inclusions, neuronal intermediate filament inclusion disease, and basophilic inclusion body disease are immunoreactive for the fused in sarcoma (FUS) protein, resulting in the creation of a new molecular subgroup (FTLD-FUS), and studies clarifying the functional consequences of pathogenic CHMP2B mutations.
Similar articles
-
A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies.Brain. 2011 Sep;134(Pt 9):2548-64. doi: 10.1093/brain/awr160. Epub 2011 Jul 12. Brain. 2011. PMID: 21752791 Free PMC article.
-
Neuronal cytoplasmic inclusions in tau, TDP-43, and FUS molecular subtypes of frontotemporal lobar degeneration share similar spatial patterns.Folia Neuropathol. 2017;55(3):185-192. doi: 10.5114/fn.2017.70482. Folia Neuropathol. 2017. PMID: 28984110
-
Diffuse argyrophilic grain disease with TDP-43 proteinopathy and neuronal intermediate filament inclusion disease: FTLD with mixed tau, TDP-43 and FUS pathologies.Acta Neuropathol Commun. 2023 Jul 6;11(1):109. doi: 10.1186/s40478-023-01611-z. Acta Neuropathol Commun. 2023. PMID: 37415197 Free PMC article.
-
Frontotemporal lobar degeneration: diversity of FTLD lesions.Rev Neurol (Paris). 2013 Oct;169(10):786-92. doi: 10.1016/j.neurol.2013.07.015. Epub 2013 Sep 12. Rev Neurol (Paris). 2013. PMID: 24035575 Review.
-
Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects.Acta Neuropathol. 2012 Sep;124(3):373-82. doi: 10.1007/s00401-012-1030-4. Epub 2012 Aug 10. Acta Neuropathol. 2012. PMID: 22878865 Free PMC article. Review.
Cited by
-
Progranulin Deficiency Reduces CDK4/6/pRb Activation and Survival of Human Neuroblastoma SH-SY5Y Cells.Mol Neurobiol. 2015 Dec;52(3):1714-1725. doi: 10.1007/s12035-014-8965-5. Epub 2014 Nov 7. Mol Neurobiol. 2015. PMID: 25377796
-
Acetylation-induced TDP-43 pathology is suppressed by an HSF1-dependent chaperone program.Nat Commun. 2017 Jul 19;8(1):82. doi: 10.1038/s41467-017-00088-4. Nat Commun. 2017. PMID: 28724966 Free PMC article.
-
Pathomorphological Diagnostic Criteria for Focal Cortical Dysplasias and Other Common Epileptogenic Lesions-Review of the Literature.Diagnostics (Basel). 2023 Mar 31;13(7):1311. doi: 10.3390/diagnostics13071311. Diagnostics (Basel). 2023. PMID: 37046529 Free PMC article. Review.
-
The genetics and neuropathology of frontotemporal lobar degeneration.Acta Neuropathol. 2012 Sep;124(3):353-72. doi: 10.1007/s00401-012-1029-x. Epub 2012 Aug 14. Acta Neuropathol. 2012. PMID: 22890575 Free PMC article. Review.
-
Pharmacotherapy for Frontotemporal Dementia.CNS Drugs. 2021 Apr;35(4):425-438. doi: 10.1007/s40263-021-00813-0. Epub 2021 Apr 11. CNS Drugs. 2021. PMID: 33840052 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources